1280191-91-4

Upstream product

• 1218781-83-9 (1R,3S)-1-(benzyloxymethyl)-3-(hydroxyl-methyl)-7-methoxy-6-methyl-1,2,3,4-tetra-hydroisoquinolin-8-ol 
• 1177255-37-6 (S)-3-(2-bromo-5-(tert-butyldimethylsilyloxy)-4-methoxy-3-methylphenyl)-2-(tert-butoxycarbonylamino)propanoic acid 
• 1280191-90-3 C₅₄H₈₇BrN₂O₉Si₃ 
• 686776-27-2 (S)-5-(2-amino-3-hydroxypropyl)-2-methoxy-3-methylphenol 
• 60656-87-3 benzyloxyacetoaldehyde 
• 1280191-58-3 C₄₈H₇₃BrN₂O₉Si₂ 

Downstream Products

• 1280191-60-7 C₃₆H₄₃BrN₂O₉ 
• 1280191-88-9 C₃₇H₃₈N₂O₁₂ 
• 1280191-81-2 C₃₄H₃₁FN₂O₉ 
• 1280191-80-1 C₃₅H₃₄N₂O₁₀ 
• 1280191-75-4 C₃₂H₃₀N₂O₉ 
• 1280191-70-9 C₃₅H₃₆N₂O₁₂ 

Relevant academic research and scientific papers

Asymmetric total synthesis of three stereoisomers of (-)-renieramycin G and their cytotoxic activities

(-)-Renieramycin G, a marine antitumor natural product, is a typical member of the bis-tetrahydroisoquinoline alkaloid family. In this paper, an efficient protocol of asymmetric total synthesis of its three stereoisomers, (+)-renieramycin G, 11,13-epi-(+)-renieramycin G and 11,13-epi-(-)-renieramycin G was established by the use of a combination of l- and/or d-tyrosine as the starting materials. The preliminary cytotoxicity assays tested on human cancer cell lines revealed that the L-shaped topological configuration of (-)-renieramycin G played a critical role in its cytotoxic activity.